As a first-line drug for AD, ChEIs can increase cholinergic transmission through reversible and noncompetitive inhibition of synaptic cholinesterase, thereby improving cognitive function, neuropsychiatric symptoms, and ability of daily living in mild and moderate patients (Jann, 1998; Birks and Grimley Evans, 2015). Here, BCHE is linked to Alzheimer disease.